at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
Company profile
Ticker
GLYC
Exchange
Website
CEO
Rachel King
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GLYC stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
S-8
Registration of securities for employees
27 Mar 24
8-K
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
PRE 14A
Preliminary proxy
22 Mar 24
8-K
Regulation FD Disclosure
1 Mar 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
8-K
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
Transcripts
GLYC
Earnings call transcript
2023 Q4
27 Mar 24
GLYC
Earnings call transcript
2023 Q3
3 Nov 23
GLYC
Earnings call transcript
2023 Q2
2 Aug 23
GLYC
Earnings call transcript
2023 Q1
3 May 23
GLYC
Earnings call transcript
2022 Q4
29 Mar 23
GLYC
Earnings call transcript
2022 Q3
9 Nov 22
GLYC
Earnings call transcript
2022 Q2
3 Aug 22
GLYC
Earnings call transcript
2022 Q1
30 Apr 22
GLYC
Earnings call transcript
2021 Q4
3 Mar 22
GLYC
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
DANIEL M JUNIUS
2 Apr 24
4
Rachel K. King
2 Apr 24
4
Mark Alan Goldberg
2 Apr 24
SC 13D/A
NEW ENTERPRISE ASSOCIATES 10 L P
29 Feb 24
SC 13D/A
NEW ENTERPRISE ASSOCIATES 10 L P
12 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
29 Jan 24
4
Bruce S Johnson
17 Jan 24
4
Harout Semerjian
17 Jan 24
4
Edwin Rock
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 49.41 mm | 49.41 mm | 49.41 mm | 49.41 mm | 49.41 mm | 49.41 mm |
Cash burn (monthly) | 2.88 mm | 184.76 k | 3.27 mm | 3.36 mm | 2.89 mm | 2.93 mm |
Cash used (since last report) | 19.12 mm | 1.23 mm | 21.74 mm | 22.32 mm | 19.24 mm | 19.48 mm |
Cash remaining | 30.29 mm | 48.18 mm | 27.67 mm | 27.08 mm | 30.17 mm | 29.92 mm |
Runway (months of cash) | 10.5 | 260.8 | 8.5 | 8.1 | 10.4 | 10.2 |
Institutional ownership, Q3 2023
86.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 53 |
Opened positions | 7 |
Closed positions | 10 |
Increased positions | 7 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 37.57 bn |
Total shares | 55.81 mm |
Total puts | 20.70 k |
Total calls | 231.50 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 9.54 mm | $35.89 mm |
BVF | 9.54 mm | $14.32 bn |
Artal | 8.59 mm | $12.88 mm |
Artal International S.C.A. | 6.57 mm | $21.43 mm |
New Enterprise Associates 10 L P | 4.97 mm | $16.64 mm |
NEA Management | 4.76 mm | $7.15 bn |
Octagon Capital Advisors | 3.00 mm | $4.50 bn |
Vanguard | 2.42 mm | $3.63 bn |
AXAHF Axa | 1.63 mm | $2.44 bn |
Acadian Asset Management | 844.05 k | $1.27 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Junius Daniel M | Common Stock | Grant | Acquire A | No | No | 3 | 5,209 | 15.63 k | 98,459 |
29 Mar 24 | Goldberg Mark Alan | Common Stock | Grant | Acquire A | No | No | 3 | 4,584 | 13.75 k | 24,828 |
12 Jan 24 | Bruce S Johnson | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.11 | 250,000 | 777.50 k | 250,000 |
12 Jan 24 | Harout Semerjian | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.11 | 695,000 | 2.16 mm | 695,000 |
12 Jan 24 | Edwin Rock | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.11 | 250,000 | 777.50 k | 250,000 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
HC Wainwright & Co. Maintains Buy on GlycoMimetics, Maintains $8 Price Target
27 Mar 24
GlycoMimetics Q4 EPS $(0.14) Beats $(0.15) Estimate, Cash Balance of $41.8M
27 Mar 24
Earnings Scheduled For March 27, 2024
27 Mar 24